Market Cap 512.00M
Revenue (ttm) 0.00
Net Income (ttm) -159.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.59
Volume 47,600
Avg Vol 179,166
Day's Range N/A - N/A
Shares Out 63.37M
Stochastic %K 97%
Beta 0.52
Analysts Strong Sell
Price Target $35.00

Latest News on ABVX

Abivax Publishes 2025 Financial Calendar

Jan 28, 2025, 2:30 AM EST - 26 days ago

Abivax Publishes 2025 Financial Calendar


Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 19, 2024, 4:30 PM EST - 3 months ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq


Abivax presents third quarter 2024 key financial information

Nov 14, 2024, 4:01 PM EST - 3 months ago

Abivax presents third quarter 2024 key financial information


Abivax presents first-half 2024 financial results

Sep 9, 2024, 4:01 PM EDT - 5 months ago

Abivax presents first-half 2024 financial results


Abivax Provides Operational and Key Program Update

Jul 15, 2024, 4:00 PM EDT - 7 months ago

Abivax Provides Operational and Key Program Update


Abivax reports 2023 financial results and operational update

Apr 2, 2024, 2:30 AM EDT - 11 months ago

Abivax reports 2023 financial results and operational update


Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Oct 26, 2023, 4:00 AM EDT - 1 year ago

Citi Appointed as Depositary Bank for Abivax SA's ADR Program


Abivax increases size of Nasdaq uplisting deal

Oct 19, 2023, 6:48 AM EDT - 1 year ago

Abivax increases size of Nasdaq uplisting deal


Abivax Readies $250 Million U.S. IPO For Drug Pipeline

Oct 18, 2023, 5:20 PM EDT - 1 year ago

Abivax Readies $250 Million U.S. IPO For Drug Pipeline


Abivax SA Starts U.S. IPO Process

Oct 3, 2023, 1:05 PM EDT - 1 year ago

Abivax SA Starts U.S. IPO Process